In the past 2- 3 decades, biologics have become an important part of
While these have proven well in treatment, cost for the patient is very high due to heavy drug development expenditure.
An alternative to biologicals is “biosimilars,” which are copies of biologicals and less expensive than the reference
biological.
Biosimilars come into the picture when the patents for biologicals expire. Biosimilars are not exactly same as the original reference drug and cannot be called as generic versions of biologic agents.